Medical devices, healthcare technology and the business of care
PMA approval · P930027

IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS

Siemens Healthcare Diagnostics, Inc. · Decision date Sep 15, 1995

MEDTECHLEDGER EXPLANATIONP930027

What did the FDA approve?

FDA record P930027 shows a decision date of September 15, 1995, with the decision field reading "APPR." The statement field says "APPROVAL FOR THE COAT-A-COUNT PSA IRMA." The device category is "Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer," and the product code is MTF.

The title names IMMULITE SYSTEMS PSA & THIRD GENERATION PSA REAGENTS, while the statement names a different product, the COAT-A-COUNT PSA IRMA. The record does not state whether this was an original PMA or a supplement, because the supplement type and supplement reason fields are absent. No clinical effectiveness or safety conclusion is present in the source.

FDA approval order statement

APPROVAL FOR THE COAT-A-COUNT PSA IRMA
Regulatory pathway
Original PMA
Clinical specialty
Immunology
Decision date
Sep 15, 1995

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P930027
Regulatory pathway
Premarket approval application
Product code
MTF
Decision code
APPR
Decision date
Sep 15, 1995
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Total, prostate specific antigen (noncomplexed & complexed) for detection of prostate cancer.

Product code
MTF
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P930027 received

    Application receipt date recorded by FDA.

  2. P930027 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P930027. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P930027

Product / regulatory recordCompanyPathwayDecision dateSource
Siemens Healthcare Diagnostics, Inc.PMA supplementSep 22, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Siemens Healthcare Diagnostics, Inc.

Headquarters
Not reported
FDA applicant address
Glyn Rhonwy, Llanberis, Gwynedd Ll55 4el, LL554EL

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records